Text Size

A combination therapy targeting endoglin and VEGF-A prevents subretinal fibro-neovascularization caused by induced müller cell disruption

Shen W., Lee S.-R., Yam M., Zhu L., Zhang T., Pye V., Mathai A.E., Shibagaki K., Zhang J.-Z., Matsugi T., Gillies M.C.

  • 2018
  • Investigative Ophthalmology and Visual Science
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Preclinical development

  • Affiliations

    The University of Sydney, Save Sight Institute Discipline of Ophthalmology, Sydney Medical School, Sydney, NSW, Australia; Department of Non-Clinical Research, Global R&D, Santen Pharmaceutical Co. Ltd., Nara, Japan

Related Publications

Atropine Ophthalmic Solution to Reduce Myopia Progression in Pediatric Subjects: The Randomized, Double-Blind Multicenter Phase II APPLE Study

Chia A, Ngo C, Choudry N, Yamakawa Y, Tan D

Efficacy of lutein supplements on macular pigment optical density in highly myopic individuals: A randomized controlled trial

Yoshida T.; Takagi Y.; Igarashi-Yokoi T.; Ohno-Matsui K.

Electrical, Electromagnetic, Ultrasound Wave Therapies, and Electronic Implants for Neuronal Rejuvenation, Neuroprotection, Axonal Regeneration, and IOP Reduction

Sharif, N.A.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022